#ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China
#ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China
#ASH25: AstraZeneca's dual-targeting CAR-T sees similar responses in Western patients as in China